Friday 22 September 2017
Contact US    |    Archive
PR
9 days ago

Novartis Cosentyx® sets the new benchmark in psoriasis with robust 5-year sustained efficacy and safety Phase III data

EAST HANOVER, N.J., Sept. 13, 2017 /PRNewswire/ -- Novartis announced today first of its kind Phase

Read on the original site


Hashtags:   

Novartis

 | 

Cosentyx®

 | 

sets

 | 

the

 | 

new

 | 

benchmark

 | 

psoriasis

 | 

with

 | 

robust

 | 
Most Popular (6 hours)

Most Popular (24 hours)

Most Popular (a week)

Categories - Countries
All News
All Countries